Acorda Therapeutics Announces Departure of Chief, Business Operations

Acorda Therapeutics Announces Departure of Chief, Enterprise Functions

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today declared that David Lawrence, Main, Business Functions and its principal accounting and monetary officer, is resigning from the Firm efficient mid-March, 2021. Mr. Lawrence will get a management place at an early-stage biotechnology company.

“Dave has been an essential part of Acorda’s leadership group about the previous 22 many years and we are grateful for the many contributions he has produced to the Enterprise,” reported Ron Cohen, Acorda’s President and CEO. “While we will pass up him, we assist his fascination in discovering a new phase of his job, and wish him very well in his next chance.”

“I am very pleased to have been aspect of assisting Acorda mature from a smaller, personal business to a community, industrial corporation that has introduced important new therapies to people today living with neurological situations, including Parkinson’s and multiple sclerosis,” reported Mr. Lawrence. “Following our just lately declared enhancements to Acorda’s monetary composition, I am leaving the company in an fantastic situation, and will be cheering it on to continued success.”

Robert Morales, Acorda’s Vice President of Finance and Controller, will presume the roles of interim principal accounting officer and interim principal financial officer.

About Acorda Therapeutics

Acorda Therapeutics develops therapies to restore perform and enhance the lives of people with neurological diseases. INBRIJA is approved for intermittent cure of OFF episodes in grown ups with Parkinson’s condition dealt with with carbidopa/levodopa. INBRIJA is not to be used by people who just take or have taken a nonselective monoamine oxidase inhibitor these types of as phenelzine or tranylcypromine within the past two weeks. INBRIJA utilizes Acorda’s impressive ARCUS® pulmonary supply procedure, a know-how platform designed to produce treatment as a result of inhalation. Acorda also marketplaces the branded AMPYRA® (dalfampridine) Extended Launch Tablets, 10 mg.

Forward-Hunting Statements

This press release consists of ahead-seeking statements. All statements, other than statements of historical information, relating to management’s expectations, beliefs, ambitions, plans or prospective clients ought to be regarded ahead-on the lookout. These statements are issue to hazards and uncertainties that could trigger real success to vary materially, including: we may not be capable to effectively marketplace AMPYRA, INBRIJA or any other items beneath advancement the COVID-19 pandemic, which includes relevant quarantines and journey restrictions, and the likely for the health issues to influence our staff members or consultants or those people that operate for other organizations we rely on, could have a substance adverse result on our small business operations or product or service revenue our potential to raise added funds to finance our functions, repay outstanding indebtedness or satisfy other obligations, and our potential to regulate our expenditures or minimize prepared expenses and take other actions which are important for us to continue on as a heading concern challenges connected with the trading of our widespread stock and our reverse stock split threats linked to our workforce, including our ability to notice the predicted benefits of our company restructuring pitfalls connected with sophisticated, regulated producing processes for prescribed drugs, which could impact whether we have ample business offer of INBRIJA to fulfill sector need our reliance on 3rd-party brands for the output of industrial materials of AMPYRA and INBRIJA third occasion payers (which includes governmental businesses) may possibly not reimburse for the use of INBRIJA or our other merchandise at satisfactory premiums or at all and may impose restrictive prior authorization necessities that limit or block prescriptions competitiveness for INBRIJA, AMPYRA and other products and solutions we may establish and current market in the foreseeable future, including increasing level of competition and accompanying decline of revenues in the U.S. from generic variations of AMPYRA (dalfampridine) adhering to our loss of patent exclusivity the ability to realize the advantages predicted from acquisitions, among the other motives simply because acquired improvement packages are usually topic to all the challenges inherent in the drug development course of action and our expertise of the threats especially applicable to acquired applications usually increases above time the possibility of unfavorable success from upcoming scientific tests of INBRIJA (levodopa inhalation powder) or from our other study and development courses, or any other obtained or in-accredited applications the occurrence of adverse protection activities with our goods the end result (by judgment or settlement) and costs of authorized, administrative or regulatory proceedings, investigations or inspections, including, without limitation, collective, consultant or course motion litigation failure to safeguard our mental home, to defend towards the mental assets claims of other folks or to get hold of 3rd bash mental residence licenses wanted for the commercialization of our products and solutions and failure to comply with regulatory demands could outcome in adverse action by regulatory agencies.

These and other risks are explained in increased depth in our filings with the Securities and Trade Commission. We might not in fact realize the targets or plans explained in our ahead-wanting statements, and traders ought to not location undue reliance on these statements. Ahead-searching statements made in this push release are made only as of the date hereof, and we disclaim any intent or obligation to update any ahead-hunting statements as a outcome of developments transpiring following the date of this push launch.